Developing The Epidemiological Evidence Base For Eczema Prevention
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
Eczema, food allergy, asthma and hay-fever are all common conditions that are a substantial burden for individuals and families. To prevent them, we need to know their causes, but these are not yet well understood. We need better studies to identify what is causing our children to develop these allergic diseases, and rigorous studies to prevent them. In this fellowship, I will explore the causes and consequences of these conditions and test ways to prevent children from developing them.
This fellowship supports continuing work on statistical methods and applications for the detection and characterization of genes involved in complex diseases, notably melanoma, but a number of related characteristics such as skin hair and eye colour, moles and freckling. The other complex disease I work on are the allergic disease, where I am involved in both human and animal based studies of allergic dermatitis and asthma.The types of data to be analysed include genome-wide genotype data and ev ....This fellowship supports continuing work on statistical methods and applications for the detection and characterization of genes involved in complex diseases, notably melanoma, but a number of related characteristics such as skin hair and eye colour, moles and freckling. The other complex disease I work on are the allergic disease, where I am involved in both human and animal based studies of allergic dermatitis and asthma.The types of data to be analysed include genome-wide genotype data and eventually whole genome sequence data.Read moreRead less
Epidemiology Of Allergic Diseases And The Role Of Early Life Eczema
Funder
National Health and Medical Research Council
Funding Amount
$416,306.00
Summary
Eczema prevents our children from getting a healthy start to life, increases their risk of developing asthma and hay-fever, and we don’t know how to prevent this condition. Dr. Lowe will help identify causes and the outcomes of eczema and allergic diseases in early life, by using a number of important research projects. This research includes an intervention trial that aims to prevent the development of allergic disease and sensitisation, which Dr Lowe leads
A Randomised Controlled Trial To Prevent Eczema, Food Allergy And Sensitisation Using A Skin Barrier Improvement Strategy
Funder
National Health and Medical Research Council
Funding Amount
$878,163.00
Summary
In this world first study, we will test if building the infant skin barrier by using daily regular skin care treatment can reduce the incidence of eczema. If successful, this trial will alter infant skin care practices and reduce the burden of allergic diseases in our community. Furthermore, as infants with eczema having a poor skin barrier, which possibly increases their risk of developing sensitisation, we will test if this intervention reduces the risk of food allergy.
BCG Immunisation To Prevent Allergy In Children: An Intervention Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,187,260.00
Summary
There has been a dramatic rise in allergic diseases (asthma, eczema, food allergy) worldwide and particularly in Australia, with up to 30% of children affected. There is evidence from small studies that BCG immunisation has beneficial effects that prevent an allergic type immune response later in life. In a large randomised trial we will determine whether BCG at birth prevents allergic disease by monitoring eczema and food sensitivity in infancy, both of which predict an allergic predisposition.
Extending The MIS BAIR Randomised Trial Of BCG To Prevent Childhood Allergy And Infection
Funder
National Health and Medical Research Council
Funding Amount
$939,504.00
Summary
BCG (used till recently to prevent tuberculosis) is a potential low cost and readily available vaccine which could reduce the rates of allergy and infection in Australian children. We propose to extend our existing NHMRC-funded trial, which studies whether BCG vaccinatinon given at birth prevents the development food allergy, eczema and infection in the 1st year of life, to see if this effect continues until 5yrs of age. At this age, we can also see if BCG vaccination at birth prevents asthma.
The aim of this proposal is to test the safety of a novel immunotherapy based on Helicobacter pylori platform technology to treat childhood allergies. Repeated oral administration of killed H. pylori mimics colonisation in the stomach and assists the development of a balanced immune system without the associated disease risk of live H. pylori. To achieve this goal Professor Barry Marshall has assembled a cross-disciplinary team of experts from Industry, Academia and Clinic.
Development And Evaluation Of Novel Anti-inflammatory Products Derived From An Indigenous Medicinal Plant
Funder
National Health and Medical Research Council
Funding Amount
$276,598.00
Summary
This collaborative project between researchers at the University of South Australia and Indigenous traditional owners from Northern Kaanju homelands (Cape York Peninsula, Qld) will develop and evaluate products derived from the Northern Kaanju medicinal plant Dodonaea polyandra. Extracts of the plant and novel compounds isolated from it have anti-inflammatory activity. These have the potential to be used in inflammatory diseases such as dermatitis, arthritis and inflammatory bowel disease.